Increase in adoption of autoimmune disease therapeutics, rise in incidence of autoimmune diseases, and availability of advanced therapeutics are expected to propel the growth of the global autoimmune disease therapeutics market.

Porland,OR, March 13, 2019 (GLOBE NEWSWIRE) -- Allied Market Research recently published a report, titled, “Autoimmune Disease Therapeutics Market by Drug Class (Anti-Inflammatory, Antihyperglycemics, NSAIDs, Interferons, and Others), Indication (Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Others) and Sales Channel (Hospital Pharmacy, Drug Store & Retail Pharmacy, and Online Store): Global Opportunity Analysis and Industry Forecast, 2018–2025.” According to the report, the global autoimmune disease therapeutics market accounted for $109.83 billion in 2017 and is estimated to garner $153.32 billion by 2025, registering a CAGR of 4.2% from 2018 to 2025.

Growth Drivers and Industry Trends

Rise in the adoption of autoimmune disease therapeutics, increase in incidence of autoimmune disease, and wide availability of advanced therapeutics are the major drivers of the global autoimmune disease therapeutics market. However, high cost associated with advanced autoimmune disease therapeutics hampers the market. On the contrary, growth opportunities in the emerging economies and strong presence of pipeline drugs are expected to create lucrative opportunities in the near future.

Request Report Sample at: https://www.alliedmarketresearch.com/request-sample/5185

The global autoimmune disease therapeutics market is divided into drug class, indication, sales channel, and geography. On the basis of drug class, the market is segmented into anti-inflammatory, antihyperglycemics, NSAIDs, interferons, and others. The anti-inflammatory segment held the largest share in 2017, contributing more than half of the total market share. Moreover, the segment is expected to register the fastest CAGR of 5.3% during the forecast period.

Segmentation Analysis of the Industry

On the basis of indication, the market is bifurcated into rheumatic disease, type 1 diabetes, multiple sclerosis, inflammatory bowel disease, and others. The rheumatic disease segment held about half of the total market share in 2017 and is expected to maintain its dominance throughout the study period. Moreover, the segment is estimated to manifest the fastest CAGR of 5.2% during the study period, owing to prevalence, surge in R&D activities, and availability of advanced therapeutics.  

Based on sale channel, the market is divided into hospital pharmacy, drug store & retail pharmacy, and online store. The drug stores & retail pharmacies segment accounted for the largest share in 2017, contributing about three-fifths of the total market revenue. However, the online stores segment is estimated to grow at a CAGR of 6.8% from 2018 to 2025, owing to rise in preference of online channels and benefits such as fewer expenses, and enhanced convenience.

Industry Key Players

The report includes analysis of the major market players such as Abbott Laboratories, AbbVie Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Novartis AG, Amgen Inc., AstraZeneca plc., Johnson & Johnson, Pfizer Inc., and UCB S.A.

About Us:

Allied Market Research (AMR) is a full-service market research and business -consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free (USA/Canada): 
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com 
Web: https://www.alliedmarketresearch.com